- 1 <u>**Title:**</u> Community Antibiotic Prescribing in Patients with COVID-19 Across Three Pandemic
- 2 Waves: A Population-Based Cohort Study
- 3
- 4 <u>Authors</u>: Laura Ciaccio¹, Peter T Donnan¹, Benjamin J Parcell², Charis A Marwick¹
- 5
- ¹ Division of Population Health and Genomics, School of Medicine, University of Dundee,
- 7 Dundee, UK.
- ⁸ ² Department of Medical Microbiology, Ninewells Hospital and School of Medicine, Dundee,
- 9 UK.
- 10
- 11 Corresponding Author:
- 12 Laura Ciaccio
- 13 University of Dundee, School of Medicine
- 14 Mailbox 1
- 15 Level 7, Corridor L
- 16 Ninewells Hospital
- 17 Dundee, DD1 9SY
- 18 Email: 2438067@dundee.ac.uk
- 19 Phone: (+44) 01382383786
- 20
- 21
- 22
- 23
- 24
- 25

26 Abstract

07		1 1 · · · · · · ·		$(1 COVID 10 1)^{-1}$
	- Rackground, Reported	i changes in antibiotic	nreserining during	the COVID-19 pandemic
	Duckground. Reported	i changes in antibiotic	presentoing during	the covin is puncenne

- 28 have focused on hospital prescribing or community population trends. Community antibiotic
- 29 prescribing for individuals with COVID-19 are less well described.
- 30 <u>Methods</u>: Data covering a complete geographic population (~800,000) were utilised. SARS-
- 31 CoV-2 virus test results from February 1, 2020- March 31, 2022 were included. Anonymised
- 32 data were linked to prescription data +/-28 days of the test, GP data for high-risk
- 33 comorbidities, and demographic data. Multivariate binary logistic regression examined
- 34 associations between patient factors and the odds of antibiotic prescription.
- 35 <u>Results</u>: Data included 768,206 tests for 184,954 individuals, identifying 16,240 COVID-19
- 36 episodes involving 16,025 individuals. There were 3,263 antibiotic prescriptions +/-28 days
- for 2,385 patients. 35.6% of patients had a prescription only before the test date, 52.5% of
- 38 patients after, and 11.9% before and after. Antibiotic prescribing reduced over time: 20.4% of
- 39 episodes in wave one, 17.7% in wave two, and 12.0% in wave three. In multivariate logistic
- 40 regression, being female (OR 1.31, 95% CI 1.19,1.45), older (OR 3.02, 95% CI 2.50, 3.68
- 41 75+ vs <25 years), having a high-risk comorbidity (OR 1.45, 95% CI 1.31, 1.61), a hospital
- 42 admission +/-28 days of an episode (OR 1.58, 95% CI 1.42, 1.77), and health board region
- 43 (OR 1.14, 95% CI 1.03, 1.25, board B versus A) increased the odds of receiving an antibiotic.
- 44 <u>Conclusion</u>: Community antibiotic prescriptions in COVID-19 episodes were uncommon in
- 45 this population and likelihood was associated with patient factors. The reduction over
- 46 pandemic waves may represent increased knowledge regarding COVID-19 treatment and/or
- 47 evolving symptomatology.
- 48
- 49
- 50

51 Introduction

- 52 Antibiotic surveillance and stewardship remain priorities during viral pandemics,¹ with the
- 53 majority of antibiotics prescribed in the community.
- 54
- 55 Many studies on antibiotic use during the COVID-19 pandemic have focused on hospitalised
- 56 patients. Systematic reviews report high rates of antibiotic prescriptions early in the pandemic
- 57 at around 70%, despite bacterial co-infection being confirmed in less than 10% of patients.¹⁻⁴
- 58

59 Studies of community antibiotic prescribing have largely described overall changes at the population level, particularly during the first pandemic wave.⁵⁻⁹ NHS England reported 60 61 antibiotic prescriptions decreased 15.5% from April 1 to August 31, 2020, compared to the 62 same period in 2019 but, adjusted for the reduction in appointments, this represented an increase of 6.7%.⁹ At the local start of the pandemic in March 2020, Scotland saw a 44% 63 64 increase in community prescriptions for antibiotics commonly used to treat respiratory 65 infections compared to 2019, but this dropped to 34% below the 2019 rate by May 2020.¹⁰ 66 Community antibiotic prescribing for individuals with COVID-19 is less well studied.^{4,10,11} 67 Of two previous relevant studies, in the US¹¹ and Italy,¹² one used diagnostic codes rather 68 69 than cases confirmed by testing and was limited to patients using one medical insurance 70 provider.¹¹ Both examined short time intervals before and after the diagnosis (so may have 71 under-estimated prescribing), and both covered only the first two pandemic waves. 72 73 This study aimed to examine community antibiotic prescribing rates across a complete 74 geographic area for people with a positive COVID-19 test across three pandemic waves, and

75 to examine health and demographic factors associated with antibiotic prescribing.

7	6
1	υ

77

78 <u>Methods</u>

- 79 Anonymised data from two National Health Service Scotland (NHS) Health Boards covering 80 approximately 20% of the Scottish population (n= 863,974) were accessed via a University of 81 Dundee Health Informatics Centre secure remote desktop. Datasets were linked at the 82 individual level using the Community Health Index (CHI) number, a unique identifier used to 83 identify patients across all NHS Scotland healthcare episodes. 84 COVID-19 test results from 28th February 2020 (date of the first COVID-19 positive test in 85 Scotland)¹³ to 31st March 2022 included Polymerase Chain Reaction (PCR) test and Lateral 86 87 Flow Test (LFT) results from NHS and private (with NHS contracts) laboratories and at-88 home tests centrally reported. Multiple tests per patient on the same day were deduplicated, 89 and repeated positive results within 90 days were considered the same episode of COVID-19, 90 in accordance with NHS Scotland testing guidance.¹⁴ 91 92 All COVID-19 episodes were linked to community antibiotic prescriptions, demography, 93 high-risk comorbidity/shielding, and hospital admission data. The community prescribing 94 dataset captures dispensed prescribed items ("prescriptions") using pharmacy claims for 95 reimbursement. Prescriptions for all oral antibiotics in the British National Formulary 96 (BNF), Chapter 5, subsections 5.1- Antibacterial Drugs, were included. Prescriptions from 28 97 days prior (-28 to -1 days) to 28 days post- (0 to +28 days) positive test were included to 98 capture pharmacy claims data batched monthly.
- 99

100	Demography data included calculated age, sex, health board, and Scottish Index of Multiple
101	Deprivation quintile (SIMD5), which is based on residential postcode. Quintile 1 is the most
102	deprived and 5 the least.
103	
104	The high-risk comorbidity dataset included patients flagged in primary care records for
105	possible shielding advice based on diagnoses and/or prescriptions. The conditions included
106	asthma, chronic obstructive pulmonary disorder (COPD), diabetes, hypertension, ischemic
107	heart disease, other respiratory conditions, and immunological conditions (supplementary
108	Table S1). All patients flagged for these conditions were considered to have high-risk
109	comorbidity.
110	
111	Hospital admissions were extracted from the Scottish Morbidity Record 01 (SMR01) dataset.
112	Admissions with a discharge date from 28 days prior to 28 days post-positive test date were
113	included.
114	
115	COVID-19 episodes were categorised into pandemic waves as previously defined for
116	Scotland, ¹⁵ with the end dates of each wave extended to prevent gaps in the study period.
117	Wave 1 started 28th February 2020, wave 2 1st August 2020, and wave 3 1st May 2021.
118	Individuals could have more than one episode, in one or more waves.
119	
120	Univariate and multivariate binary logistic regression analyses were used to examine
121	associations between health and demographic factors and the likelihood of receiving a
122	community antibiotic prescription for that COVID-19 episode. Variables included age (<25,
123	25-44, 45-64, 65-74, 75+ years), gender, health board of residence (A vs B), high-risk
124	comorbidity, hospital admissions +/-28 days, Scottish Index of Multiple Deprivation

- 125 (SIMD5) quintile, and pandemic wave. All variables were included in multivariate analysis
- 126 due to social and/or clinical relevance.
- 127
- 128 All analyses used RStudio version 4.1.2.
- 129
- 130

131 **Results**

- 132 The dataset included 768,206 tests for 184,954 individuals (21.4% of the population). There
- 133 were 16,240 COVID-19 episodes involving 16,025 individuals. 98.7% of included
- 134 individuals had one episode, 1.3% had two, and 0.01% had three. The mean age at episode
- 135 was 51.9 years (SD 24.8), 59.4% were female, and 57.2% were in health board B (Table 1).
- 136 The age distribution of episodes varied across waves, with 29.0% in wave 1 involving people
- 137 aged 75+ years, compared to 18.2% in wave 3, and 3.0% in wave 1 aged <25 years compared
- 138 to 23.0% in wave 3.
- 139
- 140 The most common comorbidities were hypertension, other respiratory disorders, and asthma.
- 141 17.4% of those with at least one episode had one high-risk comorbidity, and 2.3% of patients
- 142 had 4 or more (Figure 1).
- 143
- 144 There were 3,263 antibiotic prescriptions within 28 days of 2,395 (18.1%) episodes. 853
- 145 (35.6%) episodes had an antibiotic prescription before the test only, 1,252 (52.3%) after only,
- 146 and 290 (12.1%) both before and after. The number of antibiotic prescriptions per episode
- 147 ranged from 1 to 8, but the majority (54.5%) had one.
- 148

149	Antibiotic prescribing in COVID-19 reduced over time, at 20.4% of episodes in wave one,
150	17.7% in wave two, and 12.0% in wave three (Table 2). Amoxicillin (22.5%) and
151	doxycycline (15.1%) were most prescribed overall, accounting for 41.1% of antibiotic
152	prescriptions in wave 1, 34.8% in wave 2, and 37.8% in wave 3 (Table 1).
153	
154	In univariate logistic regression, all variables were significantly associated with the odds of
155	having a prescription (Table 3). In multivariate analysis, being female (OR 1.31, 95%CI 1.19
156	to 1.45), older (OR 3.02 [2.50 to 3.68] for 75+ vs <25 years), having a high-risk comorbidity
157	(Figure 1) (OR 1.45 [1.31 to 1.61]), having a hospital admission within 28 days of an episode
158	(OR 1.58 [1.42 to 1.77]), and living in health board B rather than A (OR 1.14 [1.03 to 1.25])
159	significantly increased the likelihood of receiving an antibiotic (Table 3). Having an episode
160	in wave 2 (OR 0.86, 95% CI 0.75 to 0.99) or wave 3 (OR 0.71, 95% CI 0.62 to 0.81)
161	significantly decreased the odds of receiving an antibiotic prescription compared to wave 1.
162	Associations with deprivation did not show a clear trend (Table 3).
163	
164	
165	Discussion
166	Principal findings
167	In this large, population-based cohort study, we saw a changing patient profile for COVID-19
168	patients over time. We found a relatively low rate of community antibiotic prescriptions for
169	COVID-19 episodes at 14.7%, with a reduction over time, from 20.4% of episodes in wave 1
170	to 12.0% in wave 3. We also found clear associations between individual demographic and
171	healthcare factors and receipt of an antibiotic.
172	

173 The decrease in antibiotic prescribing over time will have multiple contributing factors. Early 174 COVID-19 treatment guidelines were modified during the pandemic as data regarding low levels of bacterial co-infection emerged.¹⁶ Testing patterns also changed, and, as testing 175 176 became available to the public and mandated for many sectors, misdiagnosis as bacterial 177 infections became less likely. Vaccination roll-out, with attenuated symptom severity, may 178 have reduced presentations with COVID-19 to community medical services, public anxiety, 179 and clinicians' likelihood of prescribing an antibiotic. Emerging viral variants had different 180 symptoms and/or severity,¹⁷ likely affecting antibiotic prescriptions similarly to vaccination. 181 The high proportion of amoxicillin and doxycycline prescriptions aligns with Scottish guidance for the treatment of (presumed bacterial) respiratory tract infections.^{18,19} The 182 183 proportion of prescriptions for these drugs was lowest in wave two, which may reflect the 184 dominant variants in wave 2 (alpha and delta) having lower prevalence of respiratory symptoms.^{17,20} 185

186

187 Older age was the strongest demographic predictor of antibiotic prescribing, likely due to higher testing rates and lower threshold for antibiotic prescriptions.²¹ Older patients are often 188 less likely to be asymptomatic,²² and, in this study, had more hospital admissions and more 189 comorbidity. Females were more likely to have a test, consistent with other studies,²³ and 190 191 had more positive tests and more antibiotic prescriptions. This may reflect differences in 192 accessing medical care, with females reportedly contacting health services more often and 193 earlier in an illness.²⁴ The association between community prescribing and hospital 194 admissions may reflect COVID-19 episodes requiring hospitalisation having longer 195 symptoms and/or more concern and community healthcare contact. However, it may reflect 196 more vulnerable individuals having more healthcare contact in general, rather than specific 197 features of the COVID-19 episode.

198

199 Comparison with other studies

200	There are very few studies examining community antibiotic prescribing in individuals with
201	COVID-19, with more focused on changes in total community or hospital prescribing. ^{5–8,10}
202	Of 154 studies in a meta-analysis of antibiotic prescribing in COVID-19, 12 were mixed
203	inpatient and outpatient settings, but none were community only. ⁴ One outpatient study
204	completed after the previous meta-analysis examined antibiotic prescriptions for American
205	Medicare beneficiaries with prescription drug (Part D) coverage, with an outpatient visit,
206	including the Emergency Department, from April 2020 to April 2021 with a primary
207	diagnosis code of COVID-19 (U071). Of >1 million encounters, around 30% of patients
208	received an antibiotic prescription within 7 days pre- or post-visit. ¹¹ This is higher than in our
209	study (despite our longer time window pre/post-diagnosis), but the Medicare population was
210	limited to those over 65 and to the first two pandemic waves, where we also observed higher
211	rates. We have also been able to include all age groups, including children, rather than
212	focusing on older individuals who were found to have greater odds of receiving an antibiotic
213	prescription. The authors note their lack of data on underlying health conditions and hospital
214	admissions as reported limitations, ¹¹ and we found these factors were influential in
215	prescribing.
216	

216

An Italian study examined community prescriptions for 331,704 individuals with laboratoryconfirmed positive COVID-19 PCR tests from March 2020 to May 2021. Prescriptions were included from 3 days pre- to 7 days post-positive test. 23% of cases received an antibiotic, with a notable increase from 18% of cases in November 2020 to 31% in March 2021.¹² The overall rate is higher than in our study, and the increase over time is contrary to our findings, but they did not include data from wave 3.

0	0	2
L	L	Э

224	Studies examining trends in overall community antibiotic prescribing all report decreases
225	across 2020. Quarterly US data reported an overall reduction, including a decrease of 44% in
226	amoxicillin prescriptions, from calendar quarter two to quarter four. ²⁵ A study from Spain
227	reported a decrease (pooled DDD reduction) in prescribed antibiotics of 7.6% in quarter one
228	and 36.8% in quarter two of 2020 compared to the same time in 2019. ⁸ Similarly, France and
229	Canada reported overall reductions of 18.2% and 31.2%, respectively, in outpatient antibiotic
230	prescriptions in 2020 compared to 2019. ^{7,26}
231	
232	In hospital settings, early COVID-19 systematic reviews found that bacterial co-infections
233	were confirmed for only around 7-8% of patients, but 70-72% received an antibiotic. ^{1–3} An
234	April 2020 survey in Scottish hospitals found that 38.3% of patients with suspected or
235	confirmed COVID-19 were prescribed an antibiotic. ²⁷ These rates are higher than we
236	observed, but the threshold for antibiotic prescribing will be lower in hospitalised patients,
237	who are more unwell and higher risk, and they are from earlier in the pandemic.
238	
239	Strengths and limitations
240	Key strengths of this study are the size of the population-level dataset and the use of
241	administrative data, which increases generalizability and minimises the impact of any
242	missing data. SIMD was the only variable with notable missing data (8%). These data were
243	missing completely at random, with affected individuals evenly distributed across categories
244	of other variables, not affecting the findings or interpretation. Another key strength is the
245	universal use of CHI numbers (de-identified) across all NHS services, enabling multiple
246	datasets to be linked longitudinally. The timeframe of this study allows analysis of trends
247	over multiple pandemic waves. A limitation of this study is that data on the coded indication

248	for the antibiotic prescriptions were unavailable, so we have potentially included antibiotics
249	prescribed for other conditions. However, primary care coding is of variable quality and
250	utility for research, ²⁸ and patients presenting with a febrile illness coded as something else
251	but subsequently diagnosed as COVID-19 would be missed by coding. Bacteriology data
252	were not included, and some individuals may have had bacterial secondary or co-infection
253	with appropriate antibiotic treatment. However, most patients with presumed bacterial
254	respiratory tract infections, including pneumonia, never have a bacteriological diagnosis, ²⁹
255	and some bacterial pathogens can also be commensals, so bacteriology data are unlikely to
256	facilitate evaluation of appropriateness at the population level. Data on individual COVID-19
257	vaccination status were not available, but vaccine uptake was high in the study population
258	(>=85% of eligible population had 2+ doses). ¹³ The findings may not be generalisable to
259	areas with different demographic characteristics (ethnicity data were unavailable), but the
260	study regions are demographically representative of the Scottish population. Clinical
261	outcomes of COVID-19 episodes were not included but would be prone to confounding by
262	indication, as sicker patients would be more likely to both get an antibiotic prescription and
263	have an adverse outcome.
0.4	

264

265 Implications for Policy and Practice

266 The decreasing use of antibiotics found in each subsequent COVID-19 wave suggests that

267 prescribers and the public responded to changing guidance and recommendations and became

268 better at recognising and managing COVID-19. Reducing unnecessary antibiotic

269 prescriptions supports antimicrobial stewardship, and the findings align with previous work

270 indicating that vaccines to reduce symptomatic illness, including viral, can reduce antibiotic

271 prescribing.³⁰ The difference in prescribing between health boards presents an opportunity for

sharing good stewardship practice.

274	Although this study used rich, linked administrative data, GP consultation data are not
275	routinely available in Scotland, and, despite the limitations, this gap should be addressed to
276	support surveillance and research to inform practice, for example, on appropriateness of
277	antibiotic prescriptions.
278	
279	Implications for Future Research
280	This work highlights the need for more research on community management of individuals
281	with COVID-19, and the drivers of potentially unnecessary antibiotic prescribing. Qualitative
282	work with prescribers in the community could enhance understanding of practice changes
283	over time, and with individuals who had COVID-19 could enhance understanding of changes
284	in healthcare-seeking behaviour or access. It would also be of interest to examine whether
285	changes in community prescribing observed in COVID-19 are replicated for other viral
286	illnesses. These findings could inform antimicrobial stewardship and strategies, including in
287	future viral pandemics.
288	
289	
290	<u>Conclusions</u>
291	Community antibiotic prescriptions in people with COVID-19 were relatively uncommon in
292	this study population and were associated with increased age and comorbidity. There was a
293	significant reduction over time which may represent increased knowledge and experience of
294	COVID-19 and/or decreased symptom severity due to vaccination and changes in the
295	dominant variants of the virus over time.
296 297 298	

299 **Table 1: Study demographics**

Variable catego	ries	Total studyPts withpopulationtest	Pts with ≥ 1	Pts. with ≥1 episode	COVID Episodes		
v arrable catego	1105		test		Wave 1*	Wave 2*	Wave 3*
Total		863974 (100%)	184953 (21.4%)	16025 (1.9%)	2430 (0.3%)	4324 (0.5%)	9434 (1.1%)
	<25	200441 (23.2%)	30220 (16.3%)	2632 (16.4%)	81 (3.0%)	385 (8.9%)	2172 (23.0%)
	25-44	220996 (25.6%)	41959 (22.7%)	3888 (24.3%)	537 (22.1%)	940 (21.7%)	2464 (26.1%)
Age group	45-64	237115 (27.4%)	52017 (28.1%)	4337 (27.1%)	849 (34.9%)	1222 (28.3%)	2313 (24.5%)
	65-74	101797 (11.8%)	23783 (12.9%)	1417 (8.8%)	258 (10.6%)	427 (9.9%)	773 (8.2%)
	75+	103625 (12.0%)	36974 (20.0%)	3751 (23.4%)	705 (29.0%)	1350 (31.2%)	1712 (18.2%)
0	Male	426794 (49.4%)	75605 (40.9%)	6533 (40.8%)	897 (36.9%)	1549 (35.8%)	4135 (43.8%)
Sex	Female	437180 (50.6%)	109348 (59.1%)	9492 (59.2%)	1533 (63.1%)	2775 (64.2%)	5299 (56.2%)
Any high-risk comorbidity	No	630838 (73.0%)	113573 (61.4%)	9975 (62.2%)	1454 (59.8%)	2401 (55.5%)	6221 (65.9%)
	Yes	233136 (27.0%)	71381 (38.6%)	6050 (37.8%)	976 (40.2%)	1923 (44.5%)	3213 (34.1%)
YY 141 1 1	А	404094 (46.8%)	67887 (36.7%)	6882 (42.9%)	779 (32.1%)	1667 (38.6%)	4473 (47.4%)
Health board	В	459880 (53.2%)	117066 (63.3%)	9143 (57.1%)	1651 (67.9%)	2657 (61.4%)	4961 (52.6%)
	1 (most deprived)	135851 (15.7%)	30411 (16.4%)	3194 (19.9%)	426 (17.5%)	888 (20.5%)	1922 (20.4%)
	2	145538 (16.8%)	31357 (17.0%)	2839 (17.7%)	374 (15.4%)	878 (20.3%)	1604 (17.0%)
Scottish Index of Multiple Deprivation	3	153304 (17.7%)	32195 (17.4%)	2808 (17.5%)	447 (18.4%)	746 (17.3%)	1650 (17.5%)
(SIMD) quintile	4	203258 (23.5%)	46426 (25.1%)	3556 (22.2%)	649 (26.7%)	934 (21.6%)	2007 (21.3%)
	5 (least deprived)	152013 (17.6%)	29995 (16.2%)	2312 (14.4%)	317 (13.0%)	599 (13.9%)	1417 (15.0%)
	Missing Data	74010 (8.6%)	14569 (7.8%)	1316 (8.2%)	217 (8.9%)	279 (6.5%)	834 (8.8%)

300 *Individuals may appear in multiple waves and may have multiple episodes in a single wave if they

301 occur >90 days apart

302

304

305 Table 2: Testing and Antibiotic Frequencies by UK COVID-19 Wave

	Total tests	Mean tests per month	Total episodes	Episodes with antibiotic prescription(s) +/-28 days	Proportion of episodes with an antibiotic prescription +/-28 day			
Wave 1	47606	3967	2432	496	20.4%			
Wave 2	432278	48031	4330	765	17.7%			
Wave 3	288232	24019	9478	1134	12.0%			
Total	768206	30728	16240	2395	14.7%			

Wave 1: February 28, 2020- July 31, 2020; Wave 2: August 1, 2020- April 30, 2021; Wave 3: May 1, 2021-March 31, 2022 (end of study period)

308

309


310


311 Table 3: Associations between demographic and healthcare factors and the odds of a

312 community antibiotic prescription for COVID-19 episodes, from binary logistic


313 regression

Variable	Category	Frequency	Univariate OR (95% CI)	p-value	Multivariate OR (95% CI)	p-value
	<25	2652	REF	-	-	-
	25-44	3958	1.53 (1.28, 1.84)	< 0.001	1.35 (1.11, 1.64)	0.003
Age Group	45-64	4394	1.88 (1.58, 2.24)	< 0.001	1.51 (1.25, 1.84)	< 0.001
	65-74	1431	2.83 (2.32, 3.48)	< 0.001	1.91 (1.52, 2.39)	< 0.001
	75+	3805	4.89 (4.15, 5.78)	< 0.001	3.02 (2.50, 3.68)	< 0.001
Sex	Male	6599	REF	-	-	-
362	Female	9641	1.25 (1.15, 1.37)	< 0.001	1.31 (1.19, 1.45)	< 0.001
High-Risk	No	10108	REF	-	-	-
Comorbidity	Yes	6132	2.34 (2.05, 2.44)	< 0.001	1.45 (1.31, 1.61)	< 0.001
Hospital Admission	No	13047	REF	_	_	_
+/-28 days	Yes	3193	2.28 (2.07, 2.51)	< 0.001	1.58 (1.42, 1.77)	< 0.001
Health Board	А	6943	REF	-	-	-
Health Board	В	9297	1.15 (1.06, 1.26)	< 0.001	1.14 (1.03, 1.25)	0.01
	1 (most deprived)	3251	REF	-	-	-
Scottish Index of	2	2864	0.83 (0.72, 0.96)	0.01	0.81 (0.70, 0.94)	0.01
Multiple Deprivation	3	2849	1.07 (0.94, 1.24)	0.29	1.00 (0.86, 1.15)	0.99
(SIMD) quintile	4	3604	1.07 (0.94, 1.22)	0.31	0.88 (0.77, 1.01)	0.07
	5 (least deprived)	2341	0.93 (0.80, 1.09)	0.38	0.84 (0.72, 0.98)	0.03
	1	2432	REF	-	-	-
COVID Wave	2	4330	0.84 (0.74, 0.95)	0.005	0.86 (0.75, 0.99)	0.03
	3	9478	0.53 (0.47, 0.60)	< 0.001	0.71 (0.62, 0.81)	< 0.001





318



321 322

* Immunosuppression

HTN

Resp. Other

0

COPD

Diabetes

With Antibiotic

IHD

Asthma

■ Without Antibiotic

Immuno.*

323

324 Transparency declaration

325 The authors have no conflicts of interest to declare.

326 Author contributions

- 327 Concept and design: All authors. Interpretation of data: All authors. Drafting of the
- 328 manuscript: LC. Manuscript revision: All authors. Statistical analysis: LC. Administrative,
- 329 technical, or material support: All authors.

330 Acknowledgements

- 331 LC was funded by the Medical Research Foundation National PhD Training Programme in
- 332 Antimicrobial Resistance Research (MRF-145-0004-TPG-AVISO)
- 333
- 334

335 **References**

- 1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al.
- Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To
 Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis. 2020;
- 2. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a
 systematic review and meta-analysis. J Infection. 2020;81(2):266–75.
- 341 3. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al.
- Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid
 review and meta-analysis. Clin Microbiol Infec. 2020;26(12):1622–9.
- 4. Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, et al. Antibiotic
 prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol
 Infec. 2021;
- 5. King LM, Lovegrove MC, Shehab N, Tsay S, Budnitz DS, Geller AI, et al. Trends in US
- Outpatient Antibiotic Prescriptions During the Coronavirus Disease 2019 Pandemic. Clin
 Infect Dis. 2020;73(3):ciaa1896.
- 6. Buehrle DJ, Nguyen MH, Wagener MM, Clancy CJ. Impact of the Coronavirus disease
 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. Open Forum
 Infect Dis. 2020;7(12):ofaa575-.
- 353 7. Kitano T, Brown KA, Daneman N, MacFadden DR, Langford BJ, Leung V, et al. The
- 354 Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An
- 355 Interrupted Time Series Analysis. Open Forum Infect Dis. 2021;8(11):ofab533.

- 356 8. Peñalva G, Benavente RS, Pérez-Moreno MA, Pérez-Pacheco MD, Pérez-Milena A,
- 357 Murcia J, et al. Effect of the coronavirus disease 2019 pandemic on antibiotic use in primary
- 358 care. Clin Microbiol Infec. 2021;27(7):1058-60.
- 359 9. Armitage R, Nellums LB. Antibiotic prescribing in general practice during COVID-19. 360 Lancet Infect Dis. 2020;
- 361 10. Malcolm W, Seaton RA, Haddock G, Baxter L, Thirlwell S, Russell P, et al. Impact of the
- 362 COVID-19 pandemic on community antibiotic prescribing in Scotland. Jac-antimicrobial 363 Resist. 2020;2(4).
- 364 11. Tsay SV, Bartoces M, Gouin K, Kabbani S, Hicks LA. Antibiotic Prescriptions
- 365 Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to
- 366 April 2021. Jama. 2022;327(20):2018-9.
- 367 12. Belleudi V, Finocchietti M, Fortinguerra F, Filippo AD, Trotta F, Davoli M, et al. Drug
- 368 Prescriptions in the Outpatient Management of COVID-19: Evidence-Based
- 369 Recommendations Versus Real Practice. Front Pharmacol. 2022;13:825479.
- 370 13. Summary -Coronavirus (COVID-19) in the UK [Internet]. 2023 [cited 2023 March 4].
- 371 Available from: https://coronavirus.data.gov.uk/
- 372 14. COVID-19 Testing Guidance [Internet]. NHS Scotland; 2021 Jul. Available from:
- 373 https://www.southlanarkshire.gov.uk/download/downloads/id/14875/covid-
- 374 19 testing guidance.pdf
- 375 15. Leslie K, Findlay B, Ryan T, Green LI, Harvey C, Whettlock AE, et al. Epidemiology of
- 376 SARS-CoV-2 during the first three waves in Scotland: a national record linkage study. J
- 377 Epidemiol Commun H. 2023;77(1):1–8.
- 378 16. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID COVID-
- 379 19 Living guidelines: drug treatment and clinical management. Clin Microbiol Infec.
- 380 2021;28(2):222-38.
- 381 17. Looi MK. How are covid-19 symptoms changing? BMJ 2023;380:p3.
- 382 18. Adult Treatment of Infection Guidelines [Internet]. NHS Tayside; 2021 [cited 2022 Dec 383 15]. Available from:
- 384 https://www.nhstaysideadtc.scot.nhs.uk/Antibiotic%20site/pdf%20docs/Antibiotic%20hospit 385 al%20man.pdf
- 19. Seaton RA, Cooper L, Gibbons CL, Malcolm W, Choo-Kang B, Griffith D, et al. 386
- 387 Antibiotic prescribing for respiratory tract infection in patients with suspected and proven
- 388 COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals. Jac-
- 389 antimicrobial Resist. 2021;3(2):dlab078-.
- 390 20. Buttenschøn HN, Lynggaard V, Sandbøl SG, Glassou EN, Haagerup A. Comparison of
- 391 the clinical presentation across two waves of COVID-19: a retrospective cohort study. Bmc
- 392 Infect Dis. 2022;22(1):423.

- 393 21. Dadras O, SeyedAlinaghi S, Karimi A, Shamsabadi A, Qaderi K, Ramezani M, et al.
- COVID 19 mortality and its predictors in the elderly: A systematic review. Heal Sci
- 395 Reports. 2022;5(3):e657.
- 396 22. You Y, Yang X, Hung D, Yang Q, Wu T, Deng M. Asymptomatic COVID-19 infection:
- 397 diagnosis, transmission, population characteristics. Bmj Supportive Palliat Care.
- 398 2021;bmjspcare-2020-002813.
- 399 23. Stall NM, Wu W, Lapointe Shaw L, Fisman DN, Giannakeas V, Hillmer MP, et al.
- 400 Sex \square and Age \square Specific Differences in COVID \square 19 Testing, Cases, and Outcomes: A
- 401 Population Wide Study in Ontario, Canada. J Am Geriatr Soc. 2020;68(10):2188–91.
- 402 24. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K.
- The influence of gender and other patient characteristics on health care-seeking behaviour: a
 QUALICOPC study. Bmc Fam Pract. 2016;17(1):38.
- 405 25. Buehrle DJ, Wagener MM, Nguyen MH, Clancy CJ. Trends in Outpatient Antibiotic
- 406 Prescriptions in the United States During the COVID-19 Pandemic in 2020. Jama Netw
- 407 Open. 2021;4(9):e2126114.
- 408 26. Bara W, Brun-Buisson C, Coignard B, Watier L. Outpatient Antibiotic Prescriptions in
- 409 France: Patients and Providers Characteristics and Impact of the COVID-19 Pandemic.410 Antibiotics. 2022;11(5):643.
- 411 27. Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinney R, Dundas S, et al. Survey of
- 412 antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in
- 413 Scottish hospitals. J Infection. 2020;81(6):952–60.
- 414 28. Mills S, Brown-Kerr A, Buchanan D, Donnan PT, Smith BH. Hidden pain and palliative
- 415 care in general practice out-of-hours attendances by patients with advanced cancer: an
- 416 analysis of coded and uncoded free-text data. Brit J Gen Pract.
- 417 2022;73(727):BJGP.2022.0084.
- 418 29. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune IL, et al. BTS guidelines
- for the management of community acquired pneumonia in adults: update 2009. Thorax.
 2009;64(Suppl 3):iii1.
- 421 30. Vekemans J, Hasso-Agopsowicz M, Kang G, Hausdorff WP, Fiore A, Tayler E, et al.
- 422 Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A
- 423 World Health Organization Action Framework. Clin Infect Dis. 2021;73(4):e1011–7.
- 424